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Abstract
 Background—Little data are available regarding individual patients’ risk of surgical site 
infection (SSI) following mastectomy with or without immediate reconstruction. Our objective 
was to develop a risk prediction model for mastectomy-related SSI.
 Methods—We established a cohort of women < 65 years of age with mastectomy from 
1/1/2004–12/31/2011 using commercial claims data. ICD-9-CM diagnosis codes were used to 
identify SSI within 180 days after surgery. SSI risk factors were determined with multivariable 
logistic regression using derivation data from 2004-2008 and validated with 2009–2011 data using 
discrimination and calibration measures.
 Results—In the derivation cohort 595 SSIs were identified in 7,607 (7.8%) women, and 396 
SSIs were coded in 4,366 (9.1%) women in the validation cohort. Independent risk factors for SSIs 
included rural residence, rheumatologic disease, depression, diabetes, hypertension, liver disease, 
obesity, preexisting pneumonia or urinary tract infection, tobacco use disorder, smoking-related 
diseases, bilateral mastectomy, and immediate reconstruction. Receipt of home health care was 
associated with lower risk. The model performed equally in the validation cohort per 
discrimination (C statistics 0.657 and 0.649) and calibration (Hosmer-Lemeshow P=0.091 and 
0.462 for derivation and validation, respectively). Three risk strata were created based on predicted 
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SSI risk, which demonstrated good correlation with the proportion of observed infections in the 
strata.
 Conclusions—We developed and internally validated an SSI risk prediction model that can be 
used to counsel women concerning their individual risk of SSI post-mastectomy. Immediate 
reconstruction, diabetes, and smoking-related diseases were important risk factors for SSI in this 
nonelderly population of women undergoing mastectomy.
 INTRODUCTION
The most common healthcare-associated infections among hospitalized patients are surgical 
site infections (SSIs). SSIs result in significant morbidity and mortality, prolong hospital 
stays, and increase healthcare costs.; According to the National Healthcare Safety Network 
(NHSN), SSI incidence is expected to be low (1–2%) after clean procedures such as breast 
operations, but breast SSI rates reported in the literature are generally higher.
Several studies have examined independent risk factors for SSI after various breast 
operations including mastectomy and immediate or delayed breast reconstruction. Comorbid 
conditions, including obesity or increased body mass index (BMI),- diabetes;;;; or 
hyperglycemia, smoking,;;;;- heavy alcohol use,; higher ASA score,;; and history of 
radiotherapy;;;;; have been reported as risk factors for SSI after breast surgery. Longer 
duration of operation;; and implant; or autologous reconstruction;; increase the risk of SSI. 
Despite a large body of literature, the inclusion of different types of breast operations, 
inconsistent definitions of SSI, variable duration of SSI surveillance, and the often limited 
number of risk factors analyzed make it difficult to conclusively determine the most 
important factors associated with infection risk. Additionally, the generalizability of findings 
is unknown because almost all studies have been from single institution/ hospitals or 
consortiums,;;;- or were based on the American College of Surgeons National Surgical 
Quality Improvement Program (NSQIP) database.;;;-;
The goal of our study was to develop a risk prediction model for SSI following mastectomy 
with and without immediate reconstruction in a large, geographically diverse population 
representing hundreds of institutions and providers. The results could be used to more 
effectively counsel women prior to surgery about their specific risk of SSI, discuss 
personalized strategies to reduce SSI risk, and facilitate informed decision making about the 
risks and benefits of different types and timing of breast procedures.
 METHODS
 Primary Data Source
We conducted a retrospective cohort study using all fully-adjudicated claims submitted for 
reimbursement from providers, facilities, and outpatient pharmacies linked to health plan 
enrollment information from 12 Anthem–affiliated plans, including over 8 million 
nonelderly women (see Appendix). We required complete medical and prescription drug 
coverage to identify relevant underlying conditions. Women with end-stage renal disease, 
prior organ transplant, or HIV infection were excluded due to the rare nature of the 
conditions and for privacy concerns.
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 Mastectomy Patient Population
We identified the first mastectomy among insured members aged 18–64 years from 
1/1/2004–12/31/2011 using International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) and Current Procedural Terminology, 4th edition (CPT-4) 
procedure codes from inpatient and outpatient facilities and providers. The mastectomy 
patient population was further refined as reported previously. We implemented steps to 
increase the likelihood that the procedures were truly mastectomies, excluding claims 
containing CPT-4, HCPCS, or UB-04 revenue codes truncated to 4 digits and populated in 
the fields reserved for ICD-9-CM procedure codes, and claims in which a mastectomy 
procedure code was present only on one line on a single claim with no other claims on the 
same date. We also excluded mastectomy procedures that were more consistent with breast-
conserving surgery (BCS) when both were coded during the same admission. For these 
analyses, we required insurance coverage 365 days before surgery and at least 30 days post-
mastectomy to capture comorbidities and early postoperative factors associated with SSI.
 SSI and Non-Infectious Wound Complications (NIWC)
SSIs and NIWCs first recorded 2–180 days after mastectomy procedures (beginning day 1 
for hematoma) were identified using ICD-9-CM diagnosis codes from inpatient and 
outpatient facilities and provider claims, as reported previously. NIWCs included fat 
necrosis (567.82, 611.3), dehiscence (875.0, 875.1, 879.0, 879.1, 998.3, 998.32), hematoma 
(998.12), and necrosis (998.83). We censored the observation period to capture SSIs at the 
time of a subsequent breast or non-breast NHSN procedure. Since risk factors for SSIs and 
NIWCs may be similar, we excluded persons who did not have an SSI but did have an 
NIWC in risk factor analyses so that the comparison group was wound complication-free.
 Risk Factors for SSI
Potential risk factors for SSI included demographics, comorbidities (primarily using the 
Elixhauser classification), medications, and cancer-related and operative factors with clinical 
or biologic plausability for association with infection risk. We matched patients’ zip code to 
the 2000 U.S. census median household income to determine income quartile and to the 
2006 urban-rural classification scheme to determine urban-rural status. Comorbidities and 
postoperative risk factors were identified using ICD-9-CM diagnosis codes, ICD-9-CM/
CPT-4 procedure codes, and outpatient prescription drug claims (Appendix Table 1).;-
Postoperative factors in the month after surgery were not counted if first coded after an SSI. 
For postoperative home health care, we did not count home health visits for persons with an 
SSI or NIWC during the mastectomy admission as these women were likely receiving 
follow up wound care (Appendix Table 1). Cancer-related risk factors included cancer stage, 
history of breast cancer, previous radiotherapy, neoadjuvant chemotherapy, previous breast 
conserving surgery, and previous lymph node surgery (Appendix Table 1). Neoadjuvant 
chemotherapy was identified by chemotherapy claims within 60 days before mastectomy. 
We identified cancer stage using ICD-9-CM diagnosis codes on pathology claims, when 
available, as described previously.; Potential operative risk factors included unilateral versus 
bilateral mastectomy, immediate breast implant and/or flap reconstruction, sentinel node, 
and simple versus modified radical mastectomy (Appendix Table 1).
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The mastectomy population was divided into derivation and validation cohorts based on 
procedures performed from 2004–2008 and 2009–2011, respectively, to determine whether 
the model was robust to changes over time. SSI risk factors with p < 0.2 in univariable 
analysis were included in the multivariable logistic regression model with backward 
selection based on a cutoff of p < 0.075. Postoperative variables that could not be assessed 
prior to surgery were not included in the risk prediction model. We assessed 
multicollinearity by examining the tolerance values in each model to ensure independence of 
explanatory variables.
The final logistic regression model from the derivation cohort was evaluated first by 
determining the performance of the derivation model parameter estimates in the validation 
cohort. Second, the variables retained in the derivation cohort model were re-fit with the 
validation cohort, allowing the parameter estimates to vary from the derivation model. We 
used the C statistic to assess discrimination, the Hosmer-Lemeshow test; to evaluate 
calibration, and the Brier score to measure overall performance of the models. Based on the 
predicted probability of SSI in the validated model using the parameter estimates from the 
derivation cohort, we grouped women into low-, moderate-, and high-risk groups. We 
obtained similar results in a Cox proportional hazards model; hence only logistic regression 
results are presented.
All data management and analyses were performed using SAS v9.3 (SAS Institute Inc., 
Cary, NC). This study was approved by the Washington University Human Research 
Protection Office.
 RESULTS
A total of 11,973 women undergoing mastectomy met inclusion criteria for the study from 
2004 to 2011. The 180-day incidence of SSI in the population was 8.3% (595/7,607 in the 
derivation cohort and 396/4,366 in the validation cohort), and the incidence of NIWC-alone 
(without SSI) was 6.9%. The cumulative incidence of SSI after mastectomy plus implant 
reconstruction was 4.9% within 30 days, 8.6% within 90 days, and 10.2% within 180 days. 
The cumulative incidence of SSI after mastectomy without implant reconstruction (i.e., 
mastectomy only or autologous flap) was 3.5% within 30 days, 5.6% within 90 days, and 
6.5% within 180 days. For all subsequent analyses, 831 patients with an NIWC but no SSI 
were excluded in order to have a wound complication-free comparison group. The final 
populations for SSI risk factor analyses included 7,115 patients in the derivation cohort with 
595 SSI, and 4,027 patients in the validation cohort with 396 SSI (Appendix Figure 1). A 
number of factors were associated with SSI in univariable analysis (Table 1). Independent 
risk factors for SSI in the derivation model included rural patient residence, rheumatologic 
disease, depression, diabetes, hypertension, liver disease, obesity, preoperative pneumonia or 
UTI, tobacco use disorder, and smoking-related diseases (e.g., chronic obstructive 
pulmonary disease). Significant operative risk factors included bilateral mastectomy and 
immediate breast implant and flap reconstruction. Receipt of home health care after surgery 
was associated with significantly lower risk of SSI (Table 2). In post-hoc testing of the 
derivation model, the parameter estimates for tobacco use disorder and smoking-related 
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diseases were significantly different (p=0.030). The odds ratios and 95% confidence 
intervals for the various risk factors differed when the variables in the model were fit to the 
validation cohort (Table 2).
The ability of the model to discriminate between SSI and no wound complication was very 
similar in the derivation and validation cohorts (Table 3). The Brier score was near zero, 
indicating that overall the predicted values were close to the actual values in both the 
derivation and validation cohorts. The predicted probability of SSI in the model was well 
calibrated to the true outcome based on the Hosmer-Lemeshow test and observed versus 
predicted SSI (Figure 1). Observed SSI rates ranged from 2.3% to 19.0% for the lowest and 
highest deciles in the derivation cohort (Figure 1A), and from 3.7% to 19.5% in the 
validation cohort (Figure 1B).
Based on the predicted probability of SSI, women were classified into one of three risk 
strata: low (0–7.5%), moderate (7.5–15%), and high (>15%) probability of SSI risk. The 
majority of women with an observed SSI in both the derivation and validation cohorts were 
classified as moderate or high predicted risk by the risk prediction model (Table 4).
 DISCUSSION
We developed and internally validated a risk prediction model for SSI after mastectomy with 
or without immediate reconstruction. Several risk factors we identified in our large, 
geographically diverse, privately insured population are novel, while others are consistent 
with previously reported risk factors for breast SSI.
Diabetes and obesity were associated with increased risk of SSI, confirming previous 
reports.-; Our finding of a dose-response for smoking and smoking-related diseases is 
consistent with a previous observation of progressively increased risk of SSI after breast 
surgery associated with light and heavy smoking. Rheumatologic and liver disease, 
hypertension, depression, and preoperative pneumonia or urinary tract infection were also 
independent risk factors for SSI. Hypertension may be functioning as a proxy for obesity, 
since 62% of the women coded for obesity were also coded for hypertension, and obesity 
was undercoded in our dataset compared to the U.S. adult female population (4.8% versus 
36%). Alternatively, hypertension may be a proxy for cardiovascular or peripheral vascular 
disease which restrict blood flow and tissue oxygenation, increasing SSI risk. The 
association of preexisting infections at other sites with SSI was reported decades ago but has 
rarely been described since,; although identification and treatment of preadmission 
infections is considered standard practice to decrease the risk of SSI.
Bilateral mastectomy and immediate breast implant and flap reconstruction were operative 
risk factors for SSI. In previous studies, immediate implant reconstruction was associated 
with increased risk of SSI compared to mastectomy; and flap reconstruction, however 
immediate pedicled and free transverse rectus abdominis flap reconstructions were 
associated with increased risk of SSI compared to implant reconstruction in another study.
We previously reported higher risk of SSI after mastectomy with immediate reconstruction 
compared with mastectomy-only and after bilateral versus unilateral mastectomy using these 
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same data, and others have reported increased wound complications or SSI associated with 
bilateral versus unilateral mastectomy. Home health care was associated with decreased risk 
of SSI in the derivation model, controlling for other risk factors for infection. This suggests 
that home health care may be an important preventive strategy, particularly for high-risk 
women.
To our knowledge, only Kim and colleagues have reported the results of SSI risk prediction 
models for mastectomy with immediate breast reconstruction. They first used 2005-2011 
NSQIP data to develop an SSI risk prediction model containing 12 variables, including 
reconstruction type, age, BMI, higher ASA score, bleeding disorder, previous cardiac 
revascularization, diabetes, active smoking, dyspnea, and hypertension, with a c-statistic of 
0.678. Kim subsequently used plastic surgeon self-reported data from the Tracking 
Operations and Outcomes for Plastic Surgeons database to develop a SSI risk prediction 
model for immediate breast reconstruction. This model contained 9 variables available 
preoperatively (age, BMI, former or current smoker, diabetes, higher ASA score, and type of 
reconstruction) and had a c-statistic of 0.637. Neither model has been validated with 
additional internal or external datasets.
Our model using private insurer claims data included patient residence, obesity, five 
comorbid conditions, current or history of tobacco use disorder, recent infection at a distant 
site, bilateral versus unilateral surgery, type of reconstruction, and home health care. All of 
these variables are available prior to operation, including home health, which can be 
included in the risk prediction model as intent to prescribe home health after surgery 
discharge. The model had c-statistics of 0.657 and 0.649 in the derivation and validation 
datasets using the derivation cohort parameter estimates, respectively, and Brier scores were 
< 0.10 in both datasets. We performed temporal validation of the model with subsequent 
years of data using the parameter estimates from the derivation model, considered an 
intermediate method of validation, since it is external with respect to time but internal with 
respect to the information present in the data.;
The calibration of our model was not optimal with a C-statistic of about 0.65, with values 
closer to 0.8 indicating good calibration (0.5 indicating random concordance and 1.0 perfect 
concordance). In the derivation cohort, the model predicted cases better in the highest 
deciles (Figure 1A), and in the validation cohort the model performed well until the highest 
decile in which it over-predicted SSI cases (Figure 1B). Before implementing this model, 
modifications including BMI to measure obesity and more accurate information concerning 
current and past tobacco use could potentially improve its predictive ability. We have found 
that the ICD-9-CM codes for obesity are a better indicator of morbid obesity than obesity 
per se, and miss a large proportion of women with BMI between 30 and 34 (unpublished 
data). In addition, inclusion of BMI would allow for capture of a dose-response with 
increasing BMI. Use of clinical data would allow for better discrimination between active 
versus past smoking, and more accurate information on comorbidities which could improve 
the model. External validation adapting the model to clinical data with more detailed 
information concerning BMI, smoking history, and relevant comorbid conditions should be 
performed to ensure the model is robust to data collected from medical records and different 
populations.
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We grouped women into risk strata based on the predicted probability of SSI from the final 
regression model. The moderate plus high risk groups accounted for 65% of all observed 
SSI in the derivation cohort and 76% in the validation cohort. Since SSI is a relatively 
uncommon event, the percentages of women with an infection in the moderate and high risk 
groups were still relatively low at 10% and 19%, respectively. Communicating the predicted 
probability of SSI or the more general predicted risk stratum to women may be valuable 
during preoperative visits. This information can be used to discuss the most appropriate 
timing of breast reconstruction (immediate versus delayed) given the woman’s preferences 
and personal SSI risk. It can also be used to discuss personal risk reduction strategies (e.g., 
smoking cessation, losing weight before semi-elective reconstructive procedures, careful 
attention to glucose control and prevention of hyperglycemia) and guide use of preventive 
measures by physicians (e.g., home health post-discharge, delaying surgery to ensure 
resolution of preexisting infection, psychiatric referral for treatment of depression). Focusing 
additional preventive measures in the moderate and high-risk populations (SSI risk > 7.5%) 
would target 45% of the population, which would be more cost-effective for interventions 
such as post-discharge home health.
The cumulative incidence of SSI within 180 days we found in this study was high compared 
to that reported by the National Surgical Improvement Project (NSQIP),; although the 
surveillance period to identify SSI is much shorter in NSQIP (30 days) and also shorter in 
the National Healthcare Safety Network surveillance system (30 days, 90 days with an 
implant). To avoid misclassification, we used ICD-9-CM diagnosis codes in our algorithm 
specific for SSI. The use of only specific ICD-9-CM diagnosis codes may have resulted in 
under-detection of infections.; We also likely missed minor infections that did not require 
surgical treatment or intravenous antibiotics during the 90-day global surgical 
reimbursement period. Thus, our reported incidence of SSI, even though higher than 
reported by NSQIP, is likely an underestimate of the true infection rate within 180 days after 
mastectomy.
A limitation of our study is that the data were designed for administrative rather than 
research purposes. As with infection, comorbidities were likely subject to undercoding and 
misclassification, depending on whether coding influenced reimbursement or was relevant to 
the encounter. We focused on women 18–64 years who are more likely to undergo breast 
reconstruction, and thus our findings may not be generalizable to older women or younger 
women lacking private health insurance.
We identified and validated risk factors for SSI after mastectomy that could be used by 
physicians to initiate discussion with patients of their individual risk/treatment options and 
care strategies to decrease infection risk. The model could also be used to facilitate 
discussion of the patient’s role in management of comorbidities to minimize complications 
and avoid delay of oncologic treatment, and to better balance the advantages of delayed 
reconstruction in high risk women against the perceived benefit of immediate reconstruction.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Using commercial claims data, we developed validated a risk prediction model for 
surgical site infection (SSI) after mastectomy. The patient and operative risk factors for 
SSI we identified are important to assess patients’ individual risk of infection.
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Observed versus expected surgical site infection (SSI) per the risk prediction model in the 
(a) derivation and (b) validation cohorts. The y-axis represents the number of observed or 
expected SSIs divided by the number of women in the decile, as a percentage. The validation 
cohort was fit using the beta coefficients from the final derivation cohort model.
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Table 1













Age 18–35 years 20 (3.4) 292 (4.5) 0.72 (0.44, 1.20) 0.208
36–40 years 52 (8.7) 511 (7.8) 1.08 (0.75, 1.54) 0.689
41–45 years 89 (15.0) 941 (14.4) 1.00
46–50 years 117 (19.7) 1,382 (21.2) 0.90 (0.67, 1.19) 0.451
51–55 years 123 (20.7) 1,240 (19.0) 1.05 (0.79, 1.40) 0.744
56–60 years 119 (20.0) 1,261 (19.3) 1.00 (0.75, 1.33) 0.988
61–64 years 75 (12.6) 893 (13.7) 0.89 (0.64, 1.22) 0.468
Patient residence Urban 478 (80.3) 5,315 (81.5) 1.00
Rural 99 (16.6) 919 (14.1) 1.20 (0.95, 1.50) 0.120
Missing 18 (3.0) 286 (4.4) 0.70 (0.43, 1.14) 0.150
Income quartile 0–25th percentile 143 (24.0) 1,602 (24.6) 0.97 (0.76, 1.24) 0.796
26–50th percentile 152 (25.5) 1,572 (24.1) 1.05 (0.82, 1.33) 0.698
51–75th percentile 144 (24.2) 1,563 (24.0) 1.00 (0.78, 1.28) 0.996
76–100th percentile 138 (23.2) 1,497 (23.0) 1.00
Missing 18 (3.0) 286 (4.4) 0.68 (0.41, 1.13) 0.140
Comorbidities/ Medications
Anticoagulant drugs 13 (2.2) 139 (2.1) 1.03 (0.58, 1.82) 0.931
Blood loss anemia 7 (1.2) 55 (0.8) 1.40 (0.64, 3.09) 0.404
Coagulopathy 6 (1.0) 46 (0.7) 1.44 (0.61, 3.37) 0.407
Congestive heart failure 7 (1.2) 35 (0.5) 2.14 (0.95, 4.84) 0.066
Congestive heart failure drugs 22 (3.7) 129 (2.0) 1.90 (1.20, 3.01) 0.006
Deficiency anemia 39 (6.6) 462 (7.1) 0.92 (0.66, 1.29) 0.628
Depression 45 (7.6) 312 (4.8) 1.63 (1.18, 2.25) 0.003
Diabetes 76 (12.8) 379 (5.8) 2.37 (1.83, 3.08) <0.001
DMARD or biologic drugs 64 (10.8) 631 (9.7) 1.12 (0.86, 1.48) 0.397
Hypertension 242 (40.7) 1,936 (29.7) 1.62 (1.37, 1.93) <0.001
Liver disease 7 (1.2) 19 (0.3) 4.08 (1.71, 9.74) 0.002
Malnutrition/weight loss 8 (1.3) 58 (0.9) 1.52 (0.72, 3.20) 0.271
Non-breast malignancy 40 (6.7) 522 (8.0) 0.83 (0.59, 1.16) 0.267
Obesity 48 (8.1) 295 (4.5) 1.85 (1.35, 2.54) <0.001
Oral steroids 73 (12.3) 767 (11.8) 1.05 (0.81, 1.36) 0.715
Peripheral vascular disease 5 (0.8) 31 (0.5) 1.77 (0.69, 4.58) 0.236
Pneumonia or UTI 19 (3.2) 114 (1.7) 1.85 (1.13, 3.04) 0.014
Psychoses 31 (5.2) 208 (3.2) 1.67 (1.13, 2.46) 0.010
Rheumatologic disease 17 (2.9) 96 (1.5) 1.97 (1.17, 3.32) 0.011






















Skin disease 17 (2.9) 109 (1.7) 1.73 (1.03, 2.90) 0.038
Tobacco use disorder 74 (12.4) 646 (9.9) 1.29 (1.00, 1.67) 0.051
Smoking-related diseases 34 (5.7) 173 (2.7) 2.22 (1.52, 3.24) <0.001
Cancer-related
Stage of breast cancer Benign or
prophylactic
18 (3.0) 185 (2.8) 1.00
Carcinoma in situ 74 (12.4) 805 (12.4) 0.94 (0.55, 1.62) 0.836
Local 361 (60.7) 4,178 (64.1) 0.89 (0.54, 1.46) 0.639
Regional 126 (21.2) 1,199 (18.4) 1.08 (0.64, 1.81) 0.771
Metastatic 16 (2.7) 153 (2.4) 1.07 (0.53, 2.18) 0.841
Previous breast cancer 99 (16.6) 997 (15.3) 1.11 (0.88, 1.39) 0.384
Previous radiotherapy 35 (5.9) 363 (5.6) 1.06 (0.74, 1.52) 0.749
Neoadjuvant chemotherapy 71 (11.9) 813 (12.5) 0.95 (0.73, 1.23) 0.704
Previous breast-conserving
 surgery
182 (30.6) 2,108 (32.3) 0.92 (0.77, 1.11) 0.384
Previous lymph node surgery 82 (13.8) 949 (14.6) 0.94 (0.74, 1.20) 0.608
Inflammatory breast disease 13 (2.2) 91 (1.4) 1.58 (0.88, 2.84) 0.128
Operative factors
Inpatient admission 516 (86.7) 5,305 (81.4) 1.50 (1.17, 1.91) 0.001
Bilateral mastectomy 263 (44.2) 2,253 (34.6) 1.50 (1.27, 1.78) <0.001
Modified radical mastectomy 267 (44.9) 2,900 (44.5) 1.02 (0.86, 1.20) 0.853
Concurrent sentinel node
 dissection
116 (19.5) 1,427 (21.9) 0.86 (0.70, 1.07) 0.176
Concurrent breast implant 318 (53.4) 2,757 (42.3) 1.57 (1.32, 1.85) <0.001
Concurrent flap reconstruction 118 (19.8) 879 (13.5) 1.59 (1.28, 1.97) <0.001
Postoperative factors
Anemia 45 (7.6) 424 (6.5) 1.18 (0.85, 1.62) 0.319
Pneumonia or UTI 14 (2.4) 77 (1.2) 2.02 (1.13, 3.59) 0.017
Home health care 110 (18.5) 1,542 (23.7) 0.73 (0.59, 0.91) 0.004
CI confidence interval, DMARD disease-modifying antirheumatic drugs, UTI urinary tract infection.
a
Additional variables dropped due to small numbers within a cell (≤ 5) of the contingency table included previous sepsis or S. aureus infection, 
chronic renal failure, alcohol abuse, and drug abuse.
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Table 2
Multivariable Logistic Regression Model of Significant Risk Factors for Surgical Site Infection After 
Mastectomy, in the Derivation Cohort of 7,115 Women, 2004–2008 and Validation Cohort of 4,027 Women, 
2009-2011
a
Variable Category Derivation Cohort Validation Cohort
Odds Ratio (95% CI) Odds Ratio (95% CI)
b
Bilateral mastectomy 1.39 (1.16, 1.67) 1.27 (1.02, 1.59)
Breast implant
 reconstruction
1.83 (1.52, 2.21) 2.26 (1.76, 2.91)
Autologous flap
 reconstruction
2.01 (1.60, 2.51) 2.29 (1.71, 3.07)
Diabetes 2.16 (1.63, 2.87) 1.54 (1.07, 2.20)
Obesity 1.57 (1.12, 2.19) 1.46 (1.06, 2.02)
Tobacco use disorder
c 1.29 (0.99, 1.68) 1.26 (0.96, 1.65)
Smoking-related diseases 2.23 (1.50, 3.31) 1.60 (0.97, 2.64)
Depression 1.52 (1.09, 2.12) 1.18 (0.83, 1.68)
Hypertension 1.48 (1.23, 1.79) 1.79 (1.42, 2.26)
Liver disease 3.65 (1.48, 8.97) 1.80 (0.57, 5.68)
Previous pneumonia or
 urinary tract infection
1.60 (0.97, 2.66) 0.67 (0.29, 1.55)
Rheumatologic disease 1.81 (1.05, 3.09) 0.88 (0.41, 1.89)
Home health care 0.78 (0.63, 0.98) 1.10 (0.86, 1.42)
Patient residence Urban 1.00 1.00
Rural 1.35 (1.06, 1.70) 1.07 (0.79, 1.46)
Missing 0.76 (0.47, 1.24) 0.96 (0.54, 1.71)
a
All variables in the model were dichotomous (yes/no), unless otherwise noted.
b
Model used the variables from the final derivation cohort model, re-fit to the validation cohort.
c
ICD-9-CM diagnosis codes for tobacco use disorder or history of tobacco use or prescription claims for smoking deterrents. The parameter 
estimates for tobacco use disorder and smoking-related diseases were significantly different in post hoc testing (p=0.030).













Olsen et al. Page 17
Table 3
Comparison of Model Fit, Calibration, and Discrimination of Multivariable Logistic Regression Model of Risk 
Factors for Surgical Site Infection (SSI) After Mastectomy, Derivation (2004–2008) Versus Validation Cohort 
(2009–2011)
Derivation Cohort











Hosmer-Lemeshow P 0.091 0.462 0.635
C-statistic 0.657 0.649 0.669
Brier score 0.074 0.087 0.086
a
The derivation model was also fit with a more restricted set of variables (obesity, diabetes, smoking-related diseases, bilateral mastectomy, implant 
reconstruction, and flap reconstruction) to determine the impact of the additional conditions on model performance. The derivation model fit with 
the more restricted set of variables had a significantly lower C-statistic (0.637) compared to the full model above (P = 0.007), Hosmer-Lemeshow P 
= 0.775, and Brier score = 0.075.
b
The validation model was fit using the beta coefficients of all variables in the final derivation cohort model.
c
Model used the variables from the final derivation cohort model, re-fit in the validation cohort (i.e., parameter estimates allowed to vary compared 
to the derivation model).
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Table 4
Distribution of Surgical Site Infections (SSIs) Within Each Predicted Risk Strata
Derivation Cohort Validation Cohort
a
















Low Risk (0–7.5%) 206 5.3 34.6 95 5.8 24.0
Moderate Risk (7.5–15%) 278 10.4 46.7 193 10.6 48.7
High Risk (>15%) 111 18.9 18.7 108 18.9 27.3
a
Model used the beta coefficients from the final derivation cohort model in the validation cohort.
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